## Branislav Strauch

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/65889/publications.pdf

Version: 2024-02-01

44 papers

2,241 citations

257357 24 h-index 39 g-index

45 all docs

45 docs citations

45 times ranked

2502 citing authors

#	Article	IF	CITATIONS
1	Establishing reference values for central blood pressure and its amplification in a general healthy population and according to cardiovascular risk factors. European Heart Journal, 2014, 35, 3122-3133.	1.0	249
2	Prevalence of primary hyperaldosteronism in moderate to severe hypertension in the Central Europe region. Journal of Human Hypertension, 2003, 17, 349-352.	1.0	213
3	Randomized Comparison of Renal Denervation Versus Intensified Pharmacotherapy Including Spironolactone in True-Resistant Hypertension. Hypertension, 2015, 65, 407-413.	1.3	178
4	Risk Factors for Nonadherence to Antihypertensive Treatment. Hypertension, 2017, 69, 1113-1120.	1.3	150
5	High Incidence of Cardiovascular Complications in Pheochromocytoma. Hormone and Metabolic Research, 2012, 44, 379-384.	0.7	138
6	Precise assessment of noncompliance with the antihypertensive therapy in patients with resistant hypertension using toxicological serum analysis. Journal of Hypertension, 2013, 31, 2455-2461.	0.3	136
7	Biochemical Screening for Nonadherence Is Associated With Blood Pressure Reduction and Improvement in Adherence. Hypertension, 2017, 70, 1042-1048.	1.3	132
8	Increased Arterial Wall Stiffness in Primary Aldosteronism in Comparison With Essential Hypertension. American Journal of Hypertension, 2006, 19, 909-914.	1.0	96
9	Adrenalectomy Improves Arterial Stiffness in Primary Aldosteronism. American Journal of Hypertension, 2008, 21, 1086-1092.	1.0	89
10	Increased intima–media thickness of the common carotid artery in primary aldosteronism in comparison with essential hypertension. Journal of Hypertension, 2007, 25, 1451-1457.	0.3	85
11	Role of Adding Spironolactone and Renal Denervation in True Resistant Hypertension. Hypertension, 2016, 67, 397-403.	1.3	<b>7</b> 3
12	Eligibility for Renal Denervation. Hypertension, 2014, 63, 1319-1325.	1.3	61
13	The prevalence of metabolic syndrome and its components in two main types of primary aldosteronism. Journal of Human Hypertension, 2010, 24, 625-630.	1.0	57
14	Diurnal blood pressure variationin pheochromocytoma, primary aldosteronism and Cushing's syndrome. Journal of Human Hypertension, 2004, 18, 107-111.	1.0	49
15	Changes in Energy Metabolism in Pheochromocytoma. Journal of Clinical Endocrinology and Metabolism, 2013, 98, 1651-1658.	1.8	49
16	Increased blood pressure variability in pheochromocytoma compared to essential hypertension patients. Journal of Hypertension, 2005, 23, 2033-2039.	0.3	45
17	Pulse wave velocity in primary hyperparathyroidism and effect of surgical therapy. Hypertension Research, 2011, 34, 296-300.	1.5	42
18	Elevated Inflammation Markers in Pheochromocytoma Compared to Other Forms of Hypertension. NeuroImmunoModulation, 2007, 14, 57-64.	0.9	38

#	Article	IF	CITATIONS
19	Long-term effect of specific treatment of primary aldosteronism on carotid intima–media thickness. Journal of Hypertension, 2015, 33, 874-882.	0.3	35
20	Factors influencing arterial stiffness in pheochromocytoma and effect of adrenalectomy. Hypertension Research, 2010, 33, 454-459.	1.5	34
21	Vascular Disturbances in Primary Aldosteronism: Clinical Evidence. Kidney and Blood Pressure Research, 2012, 35, 529-533.	0.9	30
22	Long-term effects of adrenalectomy or spironolactone on blood pressure control and regression of left ventricle hypertrophy in patients with primary aldosteronism. JRAAS - Journal of the Renin-Angiotensin-Aldosterone System, 2015, 16, 1109-1117.	1.0	29
23	Blood Pressure Profile, Catecholamine Phenotype, and Target Organ Damage in Pheochromocytoma/Paraganglioma. Journal of Clinical Endocrinology and Metabolism, 2019, 104, 5170-5180.	1.8	28
24	Determination of doxazosin and verapamil in human serum by fast LC–MS/MS: Application to document non-compliance of patients. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2010, 878, 3167-3173.	1.2	26
25	Renal denervation in comparison with intensified pharmacotherapy in true resistant hypertension. Journal of Hypertension, 2017, 35, 1093-1099.	0.3	25
26	Importance of thorough investigation of resistant hypertension before renal denervation: should compliance to treatment be evaluated systematically? Journal of Human Hypertension, 2014, 28, 684-688.	1.0	23
27	Combination antihypertensive therapy in clinical practice. The analysis of 1254 consecutive patients with uncontrolled hypertension. Journal of Human Hypertension, 2016, 30, 35-39.	1.0	19
28	Primary Aldosteronism and Pregnancy. Kidney and Blood Pressure Research, 2020, 45, 275-285.	0.9	16
29	Increased carotid intima-media thickness in patients with pheochromocytoma in comparison to essential hypertension. Journal of Human Hypertension, 2009, 23, 350-358.	1.0	15
30	Impact of essential hypertension and primary aldosteronism on plasma brain natriuretic peptide concentration. Blood Pressure, 2006, 15, 302-307.	0.7	14
31	Discrepant Results of Adrenal Venous Sampling in Seven Patients with Primary Aldosteronism. Kidney and Blood Pressure Research, 2012, 35, 205-210.	0.9	14
32	LONG-TERM EFFECT OF ADRENALECTOMY ON CARDIOVASCULAR REMODELING IN PATIENTS WITH PHEOCHROMOCYTOMA. Journal of Clinical Endocrinology and Metabolism, 2017, 102, jc.2016-2422.	1.8	14
33	Catecholamines Induce Left Ventricular Subclinical Systolic Dysfunction: A Speckle-Tracking Echocardiography Study. Cancers, 2019, 11, 318.	1.7	13
34	Left ventricle remodeling in men with moderate to severe volume-dependent hypertension. JRAAS - Journal of the Renin-Angiotensin-Aldosterone System, 2012, 13, 426-434.	1.0	8
35	Development of a fast LC–MS/MS method for quantification of rilmenidine in human serum: elucidation of fragmentation pathways by HRMS. Journal of Mass Spectrometry, 2010, 45, 1179-1185.	0.7	7
36	Should All Patients with Resistant Hypertension Receive Spironolactone?. Current Hypertension Reports, 2016, 18, 81.	1.5	6

3

#	Article	IF	CITATIONS
37	FGF21 Levels in Pheochromocytoma/Functional Paraganglioma. Cancers, 2019, 11, 485.	1.7	2
38	Biochemical Testing After Pheochromocytoma Removal: How Early?. Hormone and Metabolic Research, 2015, 47, 633-636.	0.7	1
39	How to assess non-compliance with the pharmacotherapy in severe resistant hypertension?. Cor Et Vasa, 2011, 53, 429-432.	0.1	1
40	Adherence and blood pressure control in patients with primary aldosteronism. Blood Pressure, 2022, 31, 58-63.	0.7	1
41	We-P11:195 Comparison of carotid intima-media thickness in patients with primary and secondary hypertension. Atherosclerosis Supplements, 2006, 7, 389.	1.2	O
42	INCREASED CAROTID INTIMA MEDIA THICKNESS IN PATIENTS WITH PHEOCHROMOCYTOMA IN COMPARISON TO ESSENTIAL HYPERTENSION. Atherosclerosis Supplements, 2008, 9, 158.	1.2	0
43	Laparoscopic adrenalectomy: institutional Czech experience after almost 300 operations. European Surgery - Acta Chirurgica Austriaca, 2016, 48, 121-124.	0.3	0
44	(Prediction of long-term renal denervation efficacy). Cor Et Vasa, 2019, 61, e378-e384.	0.1	0